SHMARQL

ocrelizumab

<http://www.wikidata.org/entity/Q2013780>

anti-CD20 monoclonal antibody under development for treatment of B cell leukemia and multiple sclerosis
rdfs:label
"ocrelizumab"@en
skos:altLabel
"2H7"@en
"Ocrevus"@en
"PR-070769"@en
"R-1594"@en
"RG-1594"@en
schema:description
"anti-CD20 monoclonal antibody under development for treatment of B cell leukemia and multiple sclerosis"@en
schema:dateModified "2026-11-07T14:32:58+00:00"^^xsd:dateTime
schema:version 2565935987
wikibase:identifiers 19
wikibase:sitelinks 15
wikibase:statements 32
p:P10245 wd:statement/Q2013780-d6665a63-4b00-d4cf-3094-aeaa75baff8f
p:P10283 wd:statement/Q2013780-3E21A444-799C-4074-9EAC-3F02E8CFDD23
p:P11143 wd:statement/Q2013780-DAD03613-77FE-47A2-BA2C-AAEA90718FED
p:P129 wd:statement/Q2013780-E61C67C6-3518-4659-8EA0-A9B53303BA1E
p:P15001 wd:statement/Q2013780-54D6C486-55A1-44F9-B152-FEBDBF427F39
p:P1889 wd:statement/Q2013780-1A568172-1D85-40AE-83D2-F7554DB3CAFF
p:P2062 wd:statement/Q2013780-055F89E3-690F-4714-80CD-1A09AB4C2331
p:P2175 wd:statement/Q2013780-d652356b-47bf-df83-e50e-98b2f49ad7ba
p:P2275 wd:statement/Q2013780-8824e6f7-4f26-354e-3d12-ee8704448902
p:P231 wd:statement/Q2013780-BDA26E07-4461-4774-8CC1-095551EF8748
p:P267 wd:statement/Q2013780-BEF2F543-5C96-4087-9CCA-DE152C5F1D33
p:P279 wd:statement/Q2013780-BBA68870-FAE7-4ACF-9453-D842729B6765
p:P2868 wd:statement/Q2013780-9B5F422C-70C0-42B7-92E6-3BF025C2259B
wd:statement/Q2013780-DB216F3C-F196-4ED2-A9C4-7756ABD36068
p:P2892 wd:statement/Q2013780-3a4ec0c8-4098-3ac3-7e37-d10547c72304
p:P31 wd:statement/Q2013780-2A90C147-DD73-4D7C-888B-3FF1AFE6533C
p:P3345 wd:statement/Q2013780-6DD73980-FBF1-4254-B8A7-C81F74AD3FBC
p:P3350 wd:statement/Q2013780-af58d7dd-4ce4-816e-3868-4783588b888e
p:P366 wd:statement/Q2013780-0BDD6A20-5746-4F52-858B-06CD4C9CD129
p:P4250 wd:statement/Q2013780-03BF76C7-01F3-469F-B10F-CABDA5DBF7E1
p:P4527 wd:statement/Q2013780-1c337712-4777-b561-6541-1636c1316e97
p:P486 wd:statement/Q2013780-2411605D-1A1B-4DAE-8421-B732B9CBC398
p:P527 wd:statement/Q2013780-7381F012-246F-42A3-A28A-3F16680FEB31
p:P592 wd:statement/Q2013780-26c9d725-47ef-8d41-2106-1574da51358e
p:P595 wd:statement/Q2013780-026ca590-47b5-eda6-d4b8-2bd71962dd6b
p:P6366 wd:statement/Q2013780-EFB131A9-7E42-466D-A714-B366C4344DCC
p:P646 wd:statement/Q2013780-258631ED-BEED-4134-9F49-D180EA9FE9E5
p:P652 wd:statement/Q2013780-B452358A-14D8-4B2D-88DF-EE49B285422C
p:P715 wd:statement/Q2013780-53B79459-3792-4510-A042-47BD63C179A6
p:P7830 wd:statement/Q2013780-043B55F7-AF65-4883-BA29-6502CDBAF5DF
p:P8026 wd:statement/Q2013780-3FEF21BC-FA0A-47BA-BBBA-421060DB83C0
p:P9635 wd:statement/Q2013780-9919DA9E-1C49-4F72-8F51-B50C66316BAF
p:direct-normalized/P4527 <http://data.parliament.uk/terms/450688>
p:direct-normalized/P486 <http://id.nlm.nih.gov/mesh/C533411>
p:direct-normalized/P592 <http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL2108041>
p:direct-normalized/P6366 <https://makg.org/entity/2778843634>
wdt:P10245 "a617026"
wdt:P10283 "C2778843634"
wdt:P11143 "Ocrelizumab"
wdt:P129 Membrane spanning 4-domains A1
wdt:P15001 "RO4964913"
wdt:P1889 eculizumab
wdt:P2062 "8371"
wdt:P2175 multiple sclerosis
wdt:P2275 "ocrelizumab"@en
wdt:P231 "637334-45-3"
wdt:P267 "L04AG08"
wdt:P279 chemical compound
wdt:P2868 monoclonal antibody
immunologic factor
wdt:P2892 "C1882138"
wdt:P31 type of chemical entity
wdt:P3345 "1876366"
wdt:P3350 "8636"
wdt:P366 medication
wdt:P4250 3.29^^xsd:decimal
wdt:P4527 "450688"
wdt:P486 "C533411"
wdt:P527 carbon
wdt:P592 "CHEMBL2108041"
wdt:P595 "7580"
wdt:P6366 "2778843634"
wdt:P646 "/m/027yysd"
wdt:P652 "A10SJL62JY"
wdt:P715 "DB11988"
wdt:P7830 "Ocrelizumab"
wdt:P8026 LiverTox toxicity likelihood category D
wdt:P9635 "569"
Download as:
TurtleJSON-LDRDF/XML
data from SPARQL profile: Wikidata